Imperial College London

Dr Frédéric B. Piel

Faculty of MedicineSchool of Public Health

Senior Lecturer



+44 (0)20 7594 3346f.piel




Praed StreetSt Mary's Campus






BibTex format

author = {Nnodu, O and Isa, H and Nwegbu, M and Ohiaeri, C and Adegoke, S and Chianumba, R and Ugwu, N and Brown, B and Olaniyi, J and Okocha, E and Lawson, J and Hassan, A-A and Diaku-Akinwumi, I and Madu, A and Ezenwosu, O and Tanko, Y and Kangiwa, U and Girei, A and Israel-Aina, Y and Ladu, A and Egbuzu, P and Abjah, U and Okolo, A and Akbulut-Jerada, N and Fernandez, M and Piel, F and Adekile, A},
doi = {10.1016/j.bcmd.2019.01.007},
journal = {Blood Cells, Molecules, and Diseases},
pages = {22--28},
title = {HemoTypeSC, a low-cost point-of-care testing device for sickle cell disease: promises and challenges},
url = {},
volume = {78},
year = {2019}

RIS format (EndNote, RefMan)

AB - BackgroundSickle cell disease (SCD) is a neglected burden of growing importance. >312,000 births are affected annually by sickle cell anaemia (SCA). Early interventions such as newborn screening, penicillin prophylaxis and hydroxyurea can substantially reduce the mortality and morbidity associated with SCD. Nevertheless, their implementation in African countries has been mostly limited to pilot projects. Recent development of low-cost point-of-care testing (POCT) devices for sickle haemoglobin (HbS) could greatly facilitate the diagnosis of those affected.MethodsWe conducted the first multi-centre, real-world assessment of a low-cost POCT device, HemoTypeSC, in a low-income country. Between September and November 2017, we screened 1121 babies using both HemoTypeSC and HPLC and confirmed discordant samples by molecular diagnosis.FindingsWe found that, in optimal field conditions, the sensitivity and specificity of the test for SCA were 93.4% and 99.9%, respectively. All 14 carriers of haemoglobin C were successfully identified. Our study reveals an overall accuracy of 99.1%, but also highlights the importance of rigorous data collection, staff training and accurate confirmatory testing. It suggests that HPLC results might not be as reliable in a resource-poor setting as usually considered.InterpretationThe use of such a POCT device can be scaled up and routinely used across multiple healthcare centres in sub-Saharan Africa, which would offer great potential for the identification and management of vast numbers of individuals affected by SCD who are currently undiagnosed.
AU - Nnodu,O
AU - Isa,H
AU - Nwegbu,M
AU - Ohiaeri,C
AU - Adegoke,S
AU - Chianumba,R
AU - Ugwu,N
AU - Brown,B
AU - Olaniyi,J
AU - Okocha,E
AU - Lawson,J
AU - Hassan,A-A
AU - Diaku-Akinwumi,I
AU - Madu,A
AU - Ezenwosu,O
AU - Tanko,Y
AU - Kangiwa,U
AU - Girei,A
AU - Israel-Aina,Y
AU - Ladu,A
AU - Egbuzu,P
AU - Abjah,U
AU - Okolo,A
AU - Akbulut-Jerada,N
AU - Fernandez,M
AU - Piel,F
AU - Adekile,A
DO - 10.1016/j.bcmd.2019.01.007
EP - 28
PY - 2019///
SN - 1079-9796
SP - 22
TI - HemoTypeSC, a low-cost point-of-care testing device for sickle cell disease: promises and challenges
T2 - Blood Cells, Molecules, and Diseases
UR -
UR -
UR -
VL - 78
ER -